This technology is exploring a new use for the NTUP413 in Alzheimer＇s disease, which has been shown to be a potential therapeutic agent for neurodegenerative diseases.

NTUP413 is a high selective HDAC6 inhibitor and well tolerated without cardiac toxicity. It decreases the levels of phosphor-tau/aggregation of tau, and reduces neuronal apoptosis. NTUP413 can ameliorate learning and memory impairment in animal models. Oral administration NTUP413 can cross the blood-brain barrier. It shows that NTUP413 has the potential to develop as an AD therapeutic drug.

NTUP413 has potent HDAC6 inhibitory activity and high selectivity for HDAC6, which can reduce side effects. Oral administration NTUP413 can penetrate blood-brain barrier; it can reduce tau phosphorylation/aggregation and significantly ameliorate learning and memory impairment by in vitro and in vivo models. It shows that NTUP413 has the potential to further develop as an AD therapeutic drug.